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Biological  and molecular  heterogeneity  of human  diseases  especially  cancers  contributes  to variations  in
treatment  response,  clinical  outcome,  and  survival.  The  addition  of new  disease-  and  condition-speciﬁc
biomarkers  to  existing  clinical  markers  to track  cancer  heterogeneity  provides  possibilities  for  further
assisting  clinicians  in predicting  clinical  outcomes  and  making  choices  of treatment  options.  Ionization
patterns  derived  from  biological  specimens  can  be adapted  for use  with  existing  clinical  markers  for  early
detection,  patient  risk  stratiﬁcation,  treatment  decision  making,  and  monitoring  disease  progression.  In
order to demonstrate  the  application  of  pyrolysis,  gas  chromatography,  and  differential  mobility  spec-
trometry  (Py-GC-DMS)  for human  diseases  to predict  the  outcome  of  diseases,  we analyzed  the  ionized
spectral  signals  generated  by  instrument  ACB2000  (ACBirox  universal  detector  2000,  ACBirox LLC,  NJ,
USA)  from  the  serum  samples  of  Mantle  Cell  Lymphoma  (MCL)  patients.  Here,  we have  used  mantle
cell  lymphoma  as  a disease  model  for  a conceptual  study  only  and  based  on the  ionization  patterns  of
the  analyzed  serum  samples,  we  developed  a  multivariate  algorithm  comprised  of  variable  selection  and
reduction  steps  followed  by  receiver  operating  characteristic  curve  (ROC)  analysis  to predict  the probabil-
ity of  a good  or  poor clinical  outcome  as  a means  of  estimating  the  likely  success  of  a particular  treatment
option.  Our  preliminary  study  performed  with  small  cohort  provides  a proof  of  concept  demonstrating
the  ability  of  this  system  to  predict  the  clinical  outcome  for  human  diseases  with  high accuracy  suggest-
ing  the  promising  application  of  pyrolysis,  gas  chromatography,  and  differential  mobility  spectrometry
 of me
ublis(Py-GC-DMS)  in the  ﬁeld
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1. Introduction
Despite advances in the treatment of hematological malignan-
cies, a subset of patients continues to develop progressive disease,
to be refractory to treatment, or to relapse shortly after treat-
ment. Hematological malignancies often pose a challenge in terms
of early detection, diagnosis, and prediction of clinical outcomes
[1]. With robust biomarker-based detection methods, extremely
sick patients can be stratiﬁed prior to treatment and recognized
as a high-risk group with poor prognosis. However, conventional
methods to detect clinical biomarkers usually involve invasive pro-
cedures for procuring blood or tissue biopsy, and require lengthy
laboratory diagnostic conﬁrmation [2]. Recently, corroborative
research efforts in the ﬁeld of oncology have led to use of molec-
ular biomarkers for early diagnosis and accurate prediction of
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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rognosis for various cancers [3]. However, no simple, rapid, and
on-invasive test exists that is capable of performing initial patient
election, accurately predicting treatment response, and assigning
he probability of good or poor outcome. We  used a technol-
gy that combines pyrolysis, gas chromatography, and differential
obility spectrometry (Py-GC-DMS) for detecting ionized particles
rom human bio-specimens derived from Mantle cell lymphoma
MCL) patients as an example to assess the diagnostic ability of
his technology to directly predict or supplement other biological
iomarkers to predict clinical outcomes.
MCL  is cytogenetically characterized by a t(11;14) transloca-
ion and a bcl-1 rearrangement resulting in the overexpression
f cyclin D1 [4–6]. Presence of complex karyotypes, deregula-
ion of key cell cycle regulators associated with p53 mutations,
DK4 activation, p16/CDKN2A inactivation, and inactivation of
NA damage response pathways are associated with aggressive
linical behavior and poor prognosis [7–9]. A high proliferation
ndex as assessed with Ki67/MIB-1 immunostaining, SOX11 over-
xpression, p53 alterations, and blastoid morphology have been
eported to predict a poor outcome in MCL  patients [10–12]. Other
erum biomarkers such as higher levels of -2 microglobulin, free
mmunoglobulin light chain in serum (either monoclonal or poly-
lonal), IL-2R, IL-8, and MIP-1 correlate with poor prognosis and
nferior outcomes [13–15]. Although morphological features along
ith genetic and serum biomarkers appear to be useful for predict-
ng outcomes, their prognostic signiﬁcance has not been conﬁrmed
n all studies [16,17]. Furthermore, assessment of overall prognosis
sing the MCL  International Prognostic Index (MIPI) lacks accuracy
nd is dependent on the treatment regimen [18]. In view of these
eﬁcits, it is evident that there is a lack of diagnostic methodology
hat can predict the clinical outcome before initiation of treatment
or MCL.
Gas chromatography (GC)-related technologies have shown
ost-effective utility in clinical diagnostic settings to resolve issues
osed by the limitations of current clinical diagnostic procedures
nd laboratory associated costs. Several GC and other related “sniff
nd tell” technologies were previously developed for detection and
iosensor related purposes [19–21]; these have included detection
f infections and diagnosis of metabolic disorders [22,23]. A com-
ination of gas chromatography and mass spectrometry (GC–MS)
as been used for cancer detection via a “breath analyzer” that
etects volatile organic compounds (VOC), which are elaborated
rom different types of cancer, including lung and breast cancers
24–26]. More recently, GC-related technologies have been more
idely applied in clinical settings to identify serum metabolites and
iomarkers for different cancer types, including gastric, colorectal,
sophageal, and pancreatic cancers [27–30]. Similarly, GC–MS tech-
ologies have also been developed for diagnosis of hematological
alignancies [31]. Ionization pattern recognition has been used in
etection technologies, and has recently been under investigation
or potential use in diagnosis of cancer and infectious diseases and
or rapid analysis of potential bioterror agents [32–36]. For detec-
ion of pathogens or markers of interest, approaches to ionization
attern recognition have used a multivariate algorithm that can
mmediately differentiate the pathogens or markers only present
n the experimental or case sets as opposed to control sets [37].
In this study, we analyzed twenty one serum samples of MCL
atients using “ionized” biochemical signatures produced by the
CB2000 instrument. Signatures were ﬁrst quantiﬁed, and the
ignal intensities were then differentiated using new multivari-
te data analysis algorithm approach and were ﬁnally associated
ith the clinical phenotype of interest to generate an ionizationignature map. In combination with analysis of DNA, protein, or
etabolite expression, the ionization signature map  may  provide
 biomarker panel that could permit patient-stratiﬁcation and pre-
iction of clinical outcome with high sensitivity and speciﬁcity. The Applied Pyrolysis 119 (2016) 189–198
ionization signature map  generated by this technology provides a
“second opinion” that is independent of existing clinical biomarkers
and established scoring systems, thus, enhancing clinical decision-
making for human diseases. We  thus illustrate the application of
pyrolysis, gas chromatography, and differential mobility spectrom-
etry system in the ﬁeld of cancer medicine.
2. Materials and methods
2.1. Study population
This study was approved by the Hackensack University Med-
ical Center’s (HUMC) Institutional Review Board (IRB) (reference
# CR00002851) and was  performed under MCL  study proto-
col number, PRO00001689 titled “Biomarker studies on Mantle
Cell Lymphoma”. Informed consents were obtained from all
patients prior to enrollment. Aliquots of serum samples obtained
under standard of care procedures were registered in the
HUMC Tissue Repository and stored at −80 ◦C. Serum samples
from untreated, newly diagnosed, chemo-naive (CN) (n = 15) and
relapsed, chemo-exposed (CE) (n = 6) MCL  patients (total n = 21)
were studied. Clinical characteristics of the patients used in this
study include leukemic phase status (increased WBC/lymphocyte
count); blastoid (presence of blastoid cells) status; MIPI score (low,
intermediate, and high); pre-treatment history (CN versus CE), type
of treatment regimen administered, clinical outcome [good out-
come (GO) versus poor outcome (PO)], progression-free survival
(PFS, from date of ﬁrst line treatment), and current status (alive or
deceased) (Supplementary ﬁle 1, Table 1).
To evaluate the system, MCL  patients were divided into
GO (n = 12/21) and PO (n = 9/21) based on a median overall
survival cut-off of 35 months irrespective of their prior treat-
ment status. Among 15 Chemo-naïve MCL  patients, 11 patients
who subsequently received chemotherapeutic regimen, HCVAD
(Hyper-fractionated–Cyclophosphamide, Vincristine, Adriamycin
and Dexamethasone) with or without rituximab as ﬁrst line
treatment (n = 11) were further divided into good outcome (GO,
n = 6/11) or poor outcome (PO = 5/11) according to the follow-
ing clinical outcome criteria: GO = relapse-free/progression free
survival > 35 months after initial treatment, or PO = more than 2
relapses or death < 35 months after initial treatment (Supplemen-
tary ﬁle 1, Table 1, gray portion). Since presence of leukemic phase,
blastoid condition, and high MIPI score in MCL  are associated with
poor prognosis, we  performed contingency analysis to determine
the association of these clinical features with the prognosis for the
MCL  cohort used in our study. Our analysis suggested that there
was no signiﬁcant association between these clinical features and
clinical outcome (as deﬁned above) in this study (Fig. 1).
2.2. ACB2000 Py-GC-DMS detection system
A serum sample (2.5 l) was  applied to the sample probe, which
was inserted into the pyro-tube (1) and heated to 300 ◦C to gen-
erate pyrolytic fragments in the vapor phase. Vaporized pyrolytic
analytes were transported by a ﬂow module (5) which injected into
the GC module (3) where the analytes were separated. The sepa-
rated analytes entered an ionization chamber inside the Differential
Mobility Spectrum (DMS) module (4), and the ionized analytes
were detected (Fig. 2). Typical DMS  settings used for separation of
analytes were based on ion differential mobility in alternating elec-
tric ﬁelds, in the compensation voltage (V) linearly increased from
−40 V to +15 V in approximately one second. Positive and negative
ion signal intensities were simultaneously recorded by DMS  at each
compensation voltage. The output spectrum generated by the DMS
consisted of 60 signal intensity values each from the negative and
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Table  1
Summary of the clinical information of the MCL  sample cohorts used in the study.
Patient
No.
Gender AGE
@ DX
Stage
@ Dx
Treatment status at
blood procurement
Leukemic
@ Dx
MIPI SCORE
1 = Low (0–3);
2 = Intermediate
(4–5); 3 = High
(6–11)
2-MG
@ Dx
Blastoid
@ Dx
1st line
Rx
PFS
(mth)
Current
Status
Clinical
Outcome
1 M 51 4 CN Y 2 6.17 N HCVAD 82.1 A GO
2  F 59 4 CN Y 3 10.3 N HCVAD 87.3 A GO
3  M 56 4 CN N 1 2.3 N HCVAD 47.3 A GO
4  M 53 4 CN N 1 1.59 Y HCVAD 69.7 A GO
5  M 43 4 CN Y 1 2.91 N HCVAD 80.3 A GO
6  M 57 4 CN Y 3 NA Y HCVAD 73.4 A GO
7  M 65 4 CN Y 1 3.54 Y P05165 66.8 A GO
8  M 60 4 CE N 2 4.81 N HCVAD 30.4 A GO
9  M 64 4 CN N 1 2.14 N HCVAD 51.5 A GO
10  M 82 4 CN Y 3 7.03 N None 36.0 D GO
11  F 28 4 CN N 1 NA N None 84 A GO
12  M 64 4 CE N 1 3.7 N HCVAD 43.8 A PO
13  M 48 4 CN N 1 1.88 N HCVAD 29.5 D PO
14  F 45 4 CN N 1 4.56 N HCVAD 12.9 D PO
15  M 55 4 CN Y 2 2.42 N HCVAD 8.3 D PO
16  F 73 4 CN Y 3 11.1 Y HCVAD 1.8 D PO
17  M 68 4 CN Y 3 7.6 N HCVAD 1.2 D PO
18  M 62 4 CE N 1 NA N FC/F 14.7 D PO
19  F 67 4 CE N 1 NA N HCVAD 18.9 D PO
20  F 65 4 CE N 1 NA N CHOP 8.7 A PO
21  F 79 4 CE Y 3 6.98 N FC/F 26.2 D PO
DX = diagnosis; M = male; F = female; CN = Chemo-naïve; CE = chemo-exposed; N = no; Y = yes; 2-MG  = 2-microglobulin; HCVAD = Hyper-fractionated−Cyclophosphamide,
Vincristine, Adriamycin and Dexamethasone; CHOP = Cyclophosphamide, Doxorubicin [hydroxydaunomycin], Predinosolone; F = Fludarabine; P–05165 = protocol # 05165;
NA  = not-available; A = alive, D = deceased
Fig. 1. Lack of association between clinical outcome and clinical features. Contingency analysis was  performed to determine the association between clinical outcome (good
or  poor) in MCL  patients and clinical markers including leukemic phase (A) (p = 0.575), blastoid condition (B) (p = 0.4135), MIPI score (C) (p = 0.7141), and  -microglobulin
( linica
F
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s
(
i
a
sD)  (p = 0.8454). No-signiﬁcant association between clinical outcome and deﬁned c
isher’s  exact test or chi-square test.
ositive ions (120 points total) acquired at an average rate of 1.5
pectra per second. The system generated a single relative intensity
RI) for each sample by adding the intensity of signals correspond-
ng to the detected ions. Each sample was run in triplicate, and
verage relative intensity from three runs was calculated for each
ample.2
l features was found. The contingency analysis was performed and analyzed using
2.3. A new multivariate data analysis approach: variable
selection and reduction using receiver operating characteristics
(VSR-ROC) curve method algorithmA new multivariate algorithm was developed using ROC statis-
tics described by Maswadeh and Snyder [37] for the classiﬁcation
and identiﬁcation of any two groups; in the current study, the
192 A.A. Inamdar et al. / Journal of Analytical and
Fig. 2. ACB2000 Py-GC-DMS detection system. The system and close-up view of the
components involved with sample processing: (1) Pyro-tube, (2) GC injector, (3)
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dapter, (8) DC input.
roups were good outcome (GO) and poor outcome (PO). The
ata analysis algorithm comprised two components. The ﬁrst com-
onent of the algorithm was variable ranking and selection; the
econd component was multivariate analysis, performed by com-
ining the highest ranked variables into a single variable, which was
sed to generate a ROC curve. The ACD (area between the curve
nd the diagonal) was calculated to separate GO and PO groups
t the maximum degree. The major variables, True Positive (TP),
alse Positive (FP), True Negative (TN), and False Negative (FN) of
OC curve statistics [37] as well as new variables unique to this
nalysis such as Percentage Separation, Positive Population Center
ikelihood (PPCL), Negative Population Center likelihood (NPCL),
onﬁdence level (CL) were further calculated for the two groups
Supplementary ﬁle 2, part A and B).
.3.1. Algorithm component 1: variable selection and ranking
Using the ACB2000 system, experimental data ﬁles were gener-
ted for serum samples of 21 MCL  patients with known clinical
utcomes (12 with good outcomes, 9 with poor outcomes). As
escribed in Supplementary ﬁle 1 (part A) each experimental data
le generated a relative intensity for each sample. Upon subtract-
ng the variables (pixels) corresponding to ionic patterns found to
ccur in common to both GO and PO groups, unique ionization sig-
atures consisting of 572 variables (pixels) were recognized. These
ariables were further used to calculate the ACD [37] between the
O and PO groups at each of 572 variables. For example, Table A1
hows the average intensity of signal for pixel (variable) # 195 for
CL  patients belonging to GO and PO groups. Fig. A1 shows the
requency plot generated using pixel signals listed in Table A1 (see
upplementary ﬁle 2, part A). Here, the frequency plot indicates a
oderate separation of good (green diamond, ) from poor (red
ox, ) clinical outcome (Supplementary ﬁle 2, Fig. A1). To improve
he distinction between GO and PO patients, the ACD were calcu-
ated for these 572 variables, and the variables that gave the best
ossible degree of separation between data-points of the GO and PO
roups were used for further analysis. The low ACD variables were
onsidered to be noise or to represent variables that were not sufﬁ-
iently sensitive to discriminate between GO and PO groups [37]. In
otal, 59 variables, representing unique biomarkers, were identiﬁed
hat were capable of distinguishing between the two groups with
 high degree of separation. These 59 variables, arranged in order Applied Pyrolysis 119 (2016) 189–198
of highest to lowest ACD, are listed in Table A2 (Supplementary ﬁle
2, part A).
2.3.2. Algorithm component 2: top-variables combination and
ROC statistics
The second component of our new multivariate data analysis
approach utilizes mathematical steps (Steps 1 through 4, which are
explained in Supplementary ﬁle 2, part B) described by Maswadeh
and Snyder [37]. In brief, a new ACD was calculated from the ACDs
of ﬁrst two  variables (for example, #195 and #197) as described
in Step 1 and Step 2 (Supplementary ﬁle 2, part A, Fig. A2) and
degree of separation was  calculated (Supplementary ﬁle 2, part A,
Fig. A3). The new ACD was  then used to calculate a second new
ACD with the next variable (Supplementary ﬁle 2, Steps 3 and 4).
This iterative process was carried on in a sequential manner, ulti-
mately reducing all 59 variables to a single variable. The ﬁnal single
variable was used to calculate an ACD representing the maximum
degree of separation between GO and PO patients (Supplementary
ﬁle 2, part A, Fig. A4). The corresponding ROC was used to calculate
major variables (TP, FP, TN, and FN) of ROC curve statistics as well
as new variables unique to this study (% Separation, PPCL, NPCL,
CL) between the GO and PO groups (See the description of steps in
Supplementary File 2, part B along with Fig. B1 and Table B1).
2.4. Data analysis
MCL  patient serum samples (n = 21) with known, good or poor
clinical outcomes (Supplementary ﬁle 1, Table 1) were analyzed
using the ACB2000 system. Each experiment was performed in trip-
licate to generate the raw data set. Raw data ﬁles of all samples
were further processed to identify ionization signature patterns
restricted to either good or poor outcome by eliminating the vari-
ables with low ACD or ionization signatures that were shared
between the two  groups. This processing by the ﬁrst component
of the VSR-ROC algorithm identiﬁed 59 variables. The second com-
ponent of the VSR-ROC algorithm reduced these 59 variables to a
single variable representing the best possible separation between
GO and PO groups. The unique ionization signatures generated after
application of the VSR-ROC algorithm were assigned to either the
good or poor outcome group based on known clinical outcome.
Then same set of MCL  serum samples (n = 21) was tested to verify
the ability of the VSR-ROC algorithm to identify patients with GO
and PO.
2.5. Statistical analysis
Data are summarized as mean ± standard error of the mean
(SEM) for relative intensity (RI) along with the probability (%P)
of patients experiencing favorable prognostic factors so as to be
labeled as good outcome (GO) or patients experiencing poor prog-
nostic factors and therefore having a poor outcome (PO). The
correlation between the clinical features and clinical outcome for
the cohort was  assessed using contingency Table. Statistical anal-
ysis was  performed using GraphPad Prism software. The details of
the statistical tests are indicated in the ﬁgure legends.
3. Results
3.1. Py-GC-DMS system generates a three-dimensional ionization
signature based on DMS signal intensity
Three-dimensional DMS  signals were plotted as a function ofion abundance (DMS signal intensity; z axis). A 2.5 l sample of
patient serum was sufﬁcient to generate 120 points that subse-
quently, separated into 60 negative and 60 positive ionized spectral
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Fig. 3. The display pattern generated by the ACB 200 Py-GC-DMS detection system. (A) Typical three-dimensional (3D) waterfall display of raw data with an average rate of
1.5  spectra/s demonstrates signiﬁcant signatures in both the negative ion-space (right yellow axis) and the positive ion-space (left green axis). (B) A two-dimensional (2D)
p incorp
p
(
f
iixel  format obtained from 3D raw data representing 572 pixels as variables being 
oints. Typical waterfall display consistent with 3D-x, y, z format
Fig. 3A) shows that ionized spectra represent ionized materials
rom patient serum sample in continuous spectrum format that
s divided into positive and negative areas. These same raw dataorated into the multivariate algorithm for calculations.
points can be converted into a 2-D ((x, y), z) pixel array format as
shown in Fig. 3B where each peak represents a sum of data points
quantifying an average intensity of pixels. All data output from
the triplicate analyses were quantitatively analyzed by Py-GC-DMS
194 A.A. Inamdar et al. / Journal of Analytical and
Table 2
Summary of clinical information on patients and relative intensity of the corre-
sponding sample detected with ACB2000 Py-GC-DMS.
Patient
No.
Chemo-naïve,
Y/N
Treatment Clinical
Outcome
Status Relative Intensity
1 Y H-CVAD GO Alive 11.6
2  Y H-CVAD GO Alive 47.5
3  Y H-CVAD GO Alive 22.0
4  Y H-CVAD GO Alive 29.4
5  Y H-CVAD GO Alive 30.6
6  Y H-CVAD GO Alive 56.0
7  Y P-05165 GO Alive 49.9
8  N H-CVAD GO Alive 27.45
9  Y H-CVAD GO Alive 29.2
10  Y None GO Dead 79.8
11  Y None GO Alive 50.55
12  N H-CVAD GO Alive 14.55
13  N H-CVAD PO Dead 14.13
14  N H-CVAD PO Dead 56.95
15  Y H-CVAD PO Dead 14.25
16  Y H-CVAD PO Dead 14.6
17  Y H-CVAD PO Dead 24.3
18  N F/FC PO Dead 65.3
19  N H-CVAD PO Dead 42.5
s
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b20  N CHOP PO Alive 86.6
21  Y F/FC PO Dead 45.9
ystem and presented as relative intensity for each patient serum
ample used in this study (Supplementary ﬁle 1, Table 2).
.2. Relative signal intensity of ionization from each outcome
roup is similar but ionized pattern is different
An individual relative intensity value for each MCL case was gen-
rated by averaging signal intensities of variables with good signal
>9% of optimized signal) from triplicate runs. The average RI val-
es for GO and PO groups were calculated by averaging the relative
ntensity of all MCL  patients sorted according to their treatment
utcomes (GO vs PO) (Supplementary ﬁle 1, Table 2). These average
I values were not signiﬁcantly different between GO (33.33 ± 5.62,
 = 12) and PO (40.50 ± 8.629, N = 9) where p = 0.4139, suggesting
hat RI values alone cannot differentiate clinical outcomes. The
verage RI value was determined for newly diagnosed chemo naïve
CN)-MCL patients prior to HCVAD (Table 2, boxed data from GO
nd PO groups). The CN-MCL patients with GO had an average RI
f 32.85 ± 6.675, N = 6, and CN-MCL patients with PO had an aver-
ge RI of 29.19 ± 9.257, N = 5, p = 0.3743 indicating that differences
etween GO and PO groups were not signiﬁcant (Fig. 4B).
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ig. 4. Analysis of correlation between relative intensity (RI) of signals and clinical outco
istory.  (B) Comparison of RI of GO and PO groups in patients who were chemo-naïve prior
ach  sample was  run in triplicate. No signiﬁcant differences in the GO and PO outcome g
ars  indicate SEM. Applied Pyrolysis 119 (2016) 189–198
3.3. In silico modiﬁcation of ionized signatures and optimization
of the multivariate algorithm increases accuracy for predicting
clinical outcome
Analysis of ionization signatures permitted identiﬁcation of a
total of 572 pixels as independent variables speciﬁc to each ioniza-
tion signal on the output grid that were unique to good or poor
outcome groups but were not shared between the two groups.
Therefore, the signature output from each GO and PO sample
was only represented by group-speciﬁc ionization points. Receiver
Operating Characteristic curve analysis was performed on these
572 pixels, and the 59 pixels with the highest ACD were selected
(Supplementary File, Table A2). These 59 variables and correspond-
ing ionization signatures were further optimized by application
of the VSR-ROC algorithm (Supplementary ﬁle 2: Part A and B).
The steps (Supplementary ﬁle 2: Part B) were repeated with all 59
selected pixels (variables) which reduced the set of variables to a
single, aggregate variable for each outcome group. The ﬁnal fre-
quency plot demonstrated the best possible separation of patient
populations with good versus poor clinical outcome (Supplemen-
tary ﬁle 2, Fig. A4). The degree of separation between good and poor
outcomes from the aggregate variable was  90%, and showed signif-
icant differences in the pattern and location of ionized signatures
between the good and poor outcome groups that could be visually
identiﬁed (Fig. 5A and B).
3.4. A new algorithm and VSR-ROC statistics on ionization
signatures identify good and poor clinical outcome MCL  patients
with high predictability and accuracy
The VSR-ROC algorithm used to construct a database of ioniza-
tion pixels with best ACD was  tested against a set of MCL  samples
with known clinical outcomes. Based on the analysis of the ionized-
signature pattern of this set of MCL  samples, the probability (%P)
of obtaining a unique ionization signature pattern speciﬁc for good
outcome or poor outcome groups was  calculated using percent GO
and percent PO from Supplementary ﬁle 1, Table 3. The probability
that a sample from a good outcome patient would show the ion-
ization signatures speciﬁc for good outcome (deﬁned as true GO)
was 88% (p < 0.0009) for all GO patients irrespective of prior treat-
ment (Fig. 6A). The probability that a sample from a poor outcome
patient would show the ionized signature speciﬁc for poor out-
come (deﬁned as true PO) was  89% (p < 0.0081) for all PO patients
irrespective of treatment (Fig. 6A). Similarly, the predictability for
samples from chemo-naïve patients treated with HCVAD regimen
GO PO
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Fig. 5. Ionization signature-pattern of MCL  samples. Ionization signatures for an MCL patient with good outcome (A) and a patient with poor outcome (B) have distinct
patterns.
Table 3
Classiﬁcation output (analysis) of MCL  training test set.
Patient No. Intensity >9% %dY-R %dY-G % PO % GO Conf-NR Conf-R Clinical Outcome
1 11.6 0 51 0 100 0 100 GO
2  47.5 5 41.5 21.5 78.5 4.5 95.5 GO
3  22.0 7 21 25 75 17 83 GO
4  29.4 0 67 0 100 9 91 GO
5  30.6 0 67.5 0 100 7 93 GO
6  56.0 0 56 0 100 15 85 GO
7  49.9 0 38 0 100 8.5 91.5 GO
8  38.8 0 85 0 100 0 100 GO
9  29.2 0 37 0 100 0 100 GO
10  79.8 0 9 0 100 0 100 GO
11  50.55 0 55 0 100 0 100 GO
12  14.55 75 0 100 0 95.5 4.5 GO
13  14.13333 34.66667 0 100 0.66666667 88.66667 11.33333 PO
14  56.95 47.5 0 100 0 100 0 PO
15  14.25 24 0 100 0 100 0 PO
16  14.6 39.5 0 100 0 100 0 PO
17  45.9 0 65 0 100 0 100 PO
18  24.3 58 0 100 0 92 8 PO
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20  42.5 14 0 100
21  86.6 92 0 100
eing true GO and PO was 92% (p = 0.004) and 80% (p = 0.1043),
espectively (Fig. 6 B). Thus, in the analysis of this set of patients,
he VSR-ROC algorithm differentiated ionization spectra that were
peciﬁc to good (11/12) or poor (8/9) clinical outcomes with accu-
acy levels of 92% and 89%, respectively, at 70% conﬁdence. Thus,
e anticipate that the spectral analysis will provide 100% accuracy
or predicting clinical outcome if the conﬁdence level is lowered.
. Discussion
Cancer is the second most common cause of death in the U.S.,
nd accounts for nearly one of every four deaths [38]. Although
here have been advancements in cancer diagnosis and manage-
ent, clinical trials and research studies indicate the need for
nnovative personalized treatment regimens, especially because
ot all patients respond to treatment or else succumb to multi-
le relapses. Unfortunately, the conventional scientiﬁc approach
lone is minimally effective, and the research communities need to
onsider alternate and innovative approaches that will supplement
nd support the clinical ﬁndings [39]. Discovery of biomarkers for
redicting clinical outcomes is gaining momentum, but a robust0 100 0 PO
0 81 19 PO
0 99 1 PO
analytical tool that can support biomarker-based conclusions as
an independent secondary method would enhance the accuracy
of diagnosis, and would be especially helpful for differentiating
patients who  are at high risk for poor clinical outcome. The avail-
ability of such a tool would facilitate patient selection, would
accelerate delivery of precision medicine, and would likely result
in better cancer care.
Pyrolysis is a form of thermolysis that couples extremely high
temperatures and an oxygen-depleted environment for optimal
vaporization of samples. Pyrolyzed analytes are further sepa-
rated by Py-GC–MS, and the resulting ionized signature represents
a unique biochemical ﬁngerprint of that speciﬁc sample. This
technology has previously been used to test bio-specimens from
humans for various purposes. Three decades of Py-GC–MS research
have improved the minimal volume required for accurate analyses
[40–42], leading to a variety of uses. For example, Py-GC–MS has
been used as a diagnostic tool to discriminate between leukemic
and normal white blood cells [43,44]; screening bacterial species
[45]; analysis of DL-lactin/glycolic acid composition for orthope-
dic use [46], and structural analysis of neuromelanin in Parkinson’s
disease [47]. More recent uses of Py-GC–MS include detection of
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Fig. 6. The ionization signature pattern speciﬁc for GO and PO groups is potentially
capable of accurately discriminating between good and poor outcome groups among
MCL  patients. (A) The probability that a sample from any patient with a GO signature
pattern irrespective of prior treatment history would truly belong to the GO group
(true GO); the probability that a sample with a PO signature pattern would truly
belong to the PO group (true PO); the probability that a sample with GO signature
would be falsely considered under the PO group (false PO) and the probability that
a  sample would be falsely considered under the GO group (false GO) were 88%,
89%, 12% and 11%, respectively. The signiﬁcance of differences between true GO and
false PO groups, and true PO and false GO was analyzed using two-tailed paired t-
test; **p < 0.01, ***p < 0.001. (B) The probability that a sample from a chemo-naive
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Tatient would be a true GO, false PO, true PO and false GO was  92%, 80%, 8% and
0%,  respectively. Signiﬁcance was analyzed using two-tailed paired t-test. NS, non-
igniﬁcant; **p < 0.01. Error bars indicate SEM.
olatile organic compounds in exhaled breath [48] and isolation of
alignant B cells from patients with chronic lymphocytic leukemia
CLL) for prognostic studies [31]. Similar to these applications, our
ata show that this technology is likely to be useful for predicting
linical outcomes from analysis of MCL  patient sera, which would
ave implications for selecting the most appropriate therapeutic
pproach.
We have selected a liquid tumor model to test and validate
he use of the Py-GC-DMS system. Because of its pathological het-
rogeneity and complexity, MCL  typically carries a poor prognosis
ith a propensity to develop drug resistance, primary treatment
ailure, and early relapse, which results in shortened survival rang-
ng from a few months to four years [49,50]. To provide better
lternative treatment options, patients who are at high risk to
xperience a poor outcome must be identiﬁed early and with
igh accuracy; however, this is a difﬁcult task with current clin-
cal methods. Current clinical markers for MCL  include cyclin
1/D2/D3, translocation status t(11;14)(q13;q32), Ki67 and SOX11.
hese parameters, in combination with ﬂow cytometric analysis for Applied Pyrolysis 119 (2016) 189–198
immuno-phenotypic patterns, cell morphology, and MIPI scores are
used for diagnostic and prognostic purposes [51,52]. For example,
SOX11 is the most recent clinical diagnostic marker for mantle cell
lymphoma, and is capable of detecting both cyclin D1-positive and -
negative MCL  cases [53]. Similarly, clinical parameters such as MIPI
score and cell morphology, although routinely used to determine
the prognosis for MCL  patients, are of marginal prognostic signiﬁ-
cance, and lack a high degree of sensitivity or speciﬁcity [18]. Even
in our cohort, we  observed that patients with a low MIPI score were
as likely to die as were patients with a high MIPI score. Similarly,
high beta-2 microglobulin, leukemic, and blastoid status failed to
correlate signiﬁcantly with clinical outcome (Supplementary ﬁle 1,
Table 1 and Fig. 1).
Our data showed that the multivariate algorithm based on Py-
GC–MS approach can potentially be applied with current diagnostic
and prognostic methods for improving accuracy for stratiﬁcation
of patients and predicting clinical outcome with high accuracy
and reliability. Optimization through multiple repetitions using
modiﬁed multivariate statistical analysis algorithms, including a
two-component VSR-ROC algorithm, was carried out to increase
the accuracy of the ionization signatures to produce a most robust
and consistent high-intensity ionization pattern, obviating the
need to maintain a large set of signatures. After optimization, typi-
cal and visually distinguishable patterns of ionization signatures of
MCL  patients belonging to good and poor clinical outcomes were
obtained (Fig. 5A and B). The results of our study indicate that the
optimized VSR-ROC algorithm and the visual display of ionization
signatures can be used in combination with clinical data sets to
differentiate patient samples according to their likely outcome.
The optimized ionization signatures speciﬁc for GO and PO
groups were then used to determine the ability to predict the clin-
ical outcome on a second set of patients (Supplementary ﬁle 1,
Table 3). Our results showed that the ionization signatures can be
further stratiﬁed to support prediction of clinical outcome for all
treatments combined or for patients receiving HCVAD treatment.
In this dataset, the probability between groups of identifying true
non-responders/PO and false responders/GO was found to be non-
signiﬁcant, mainly due to small sample size (n = 5) (Fig. 6A and B);
however, a larger cohort with greater than 100 MCL  biospecimen
would provide more false negative and positive datasets.
We expect that the high accuracy of prediction (>90%, p < 0.005)
from the current data will not be signiﬁcantly reduced as the size
of cohort is increased if the clinical outcome criteria remain the
same as used in this study. Speciﬁc ionized fragments that dif-
ferentiated good versus poor outcome groups could be further
puriﬁed via high resolution chromatographic methods and this
remains as our future goal. The purpose of this preliminary study
was to explore the utility of Py-GC-DMS-derived ionization sig-
natures based biomarkers to predict the outcome of patients as
good and poor. Although, this study has implemented small cohort
of samples which gave out large number of variables (572 sig-
nals) initially, using VSR-ROC algorithm, we were able to further
reduce them down to 59 variables capable of demonstrating the
best possible separation of patient populations with good versus
poor clinical outcome. We  understand that use of small sample
size often results into large number of variables and often over-
ﬁtting of the data occurs leading to including of variables due to
noise and some not demonstrating the real difference [54]. In this
study, we incorporated VS-ROC algorithm based statistical anal-
ysis but other statistical methods especially Partial least squares
discriminant analysis (PLSDA) coupled with various cross valida-
tion to reliably minimize the error rate and improve the accuracy
of the prediction [54]. We  are aware of such spurious correla-
tions occurring especially in situations where limited number is
present and will take into consideration optimal statistical strate-
gies by vigorously employing cross validation methods/models to
al and
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void common mistakes associated with statistical analysis with
iomarker related research in future studies with large cohort [55].
uch strategies will deﬁnitely help us to achieve higher probability
f accurate prediction for clinical outcome for the disease under
onsideration.
In summary, we ﬁnd several advantages of Py-GC-DMS-based
onization signatures for supporting current clinical MCL  mark-
rs and subsequently for any disease under consideration as an
ndependent analytical tool for guiding choices of individualized
reatment for patients. The analytic methods employed in our
tudy (1) required only 2.5 l of serum per run, (2) took less than
0 seconds for detection time, (3) eliminated any special handling
nd chemical reagents, (4) provided automation of all data pro-
essing, and (5) have the inherent capacity for addition of new
ignatures to the existing database to improve accuracy. Our study
uggests that Py-GC-DMS ionization signatures in combination
ith existing clinical markers could support clinical decisions for
reatment strategies, risk stratiﬁcation, and reducing the cost of
ancer care. As a predictive tool, this system promises to provide
nformation that will help avoid unnecessary treatment expenses
or patients with a high likelihood of being poor responders, provid-
ng for early consideration of adjuvant therapies for such high-risk
atients, and offering a convenient and rapid method for predicting
he response of an individual patient to a therapeutic agent.
. Conclusion
The Py-GC-DMS system can be readily adapted to existing clin-
cal markers to support stratiﬁcation of patients for diagnosis,
rognosis, and prediction of clinical outcomes in MCL  and possi-
ly in other cancers. The algorithm can be extrapolated to include
ore ionization proﬁles. The systematic analysis of ionization sig-
atures can provide prognostic information of high speciﬁcity and
ensitivity relevant to the patient selection process. The ionization
roﬁling can be incorporated into current clinical decision-making
s an independent technological approach, and this technology can
otentially improve point-of-screening and point-of-care clinical
rotocols.
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